European Union´s Horizon 2020 – Lipum2019-01-31T10:20:32+00:00


Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

2103, 2019

Lipum attracts interest from life science leaders

March 21st, 2019|

Lipum is attending two significant events in Vienna next week. At the RESI Europe and the BIO-Europe Spring meetings we will meet with key decision makers from the pharma and venture capital segments. These events take place March 25-27 and provides an opportunity to meet, please contact us and learn [...]

1903, 2019

Lipum and Abzena sign integrated CMC agreement

March 19th, 2019|

Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory [...]

403, 2019

Lipum to NASDAQ

March 4th, 2019|

On 6-7 March, Lipum attends a pitching event for Deep Tech companies in Stockholm hosted by The European Innovation Council (EIC) pilot and Nasdaq. The event is exclusively organised for EIC pilot- funded companies with the opportunity to pitch their business to top European investors and connect with Nasdaq representatives [...]

1602, 2019

New share issue round about to close on Sunday 17 February

February 16th, 2019|

Tomorrow, Lipum will close a share issue raising SEK 25 million in addition to support from Horizon 2020 of SEK 23 million grant. The capital will finance the preclinical work and the development of a production method up to the start of toxicology studies next year. See the full [...]

3001, 2019

Lipum on the list of Swedish startups who receive millions from the EU

January 30th, 2019|

"Sweden is number eight on the list of European countries that receive the most money" says Johan Lindberg at Vinnova, who helps Swedish companies to apply for EU grants. So far, Sweden has received SEK 10 billion through the EU Innovation Fund Horizon 2020, of which 25 million was allocated [...]

European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€